New Study of Aerin Medical’s RhinAer® Shows Positive Clinical and Quality-of-Life Results Following Treatment for Chronic Rhinitis

SUNNYVALE, Calif.--(BUSINESS WIRE)-- Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced the publication of positive results from the RELIEF clinical trial in the American Journal of Rhinology & Allergy. RELIEF demonstrated that treatment yielded a clinically significant improvement in all chronic rhinitis symptoms and quality-of-life (QoL) at three- and six-months following RhinAer^® treatment. Additionally, the study demonstrated that the procedure was well-tolerated by patients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220719005048/en/

Results of the RELIEF clinical trial published in the American Journal of Rhinology & Allergy confirm that treatment with RhinAer® provides significant reduction in chronic rhinitis symptoms and improvement in quality-of-life. RhinAer, a non-invasive technology developed by Aerin Medical Inc., uses temperature-controlled radiofrequency energy to provide long-term relief from chronic rhinitis. (Photo: Business Wire)

“Chronic rhinitis can be a frustrating condition for patients as the symptoms are often poorly controlled with current treatments like nasal sprays and other medications,” said Elina Toskala, M.D., Ph.D., MBA, Professor, Rhinology and Skull Base Surgery, Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University in Philadelphia, and investigator of the RELIEF clinical trial. “This new international, multi-center study demonstrates that treatment with a temperature-controlled radiofrequency device shows a sustained improvement in chronic rhinitis symptoms, cough and post-nasal drip as well as quality-of-life measures through 6 months. The procedure was shown to be well-tolerated with no post-procedural headaches reported."

RELIEF, a prospective, single-arm, multi-center study, enrolled 129 adults with chronic rhinitis at 16 centers in the United States and Germany and evaluated clinical outcomes and QoL in those who were treated with RhinAer. The RELIEF study met its primary and secondary endpoints, demonstrating that treatment of the posterior nasal nerve (PNN) area with RhinAer was safe and significantly reduced major chronic rhinitis symptoms at three- and six-months following treatment. Findings included:

• Symptom Improvement: There was a 62.8% improvement over baseline at six months and 53.8% improvement at three months (p<0.001 comparing each follow up to baseline) in reflective total nasal symptom score (rTNSS) subscores (runny nose, nasal congestion, itching and sneezing). Post-nasal drip and chronic cough scores were significantly improved at three months and further improved at six months.
• Responder Rates: 83.5% of patients positively responded to treatment in the six-month analysis and 76.2% at three months, defined as a ≥30% improvement in symptoms compared to baseline.
• Quality-of-Life Improvement: At six months, 87.7% of participants reported a minimal clinically important difference (MCID) of ≥0.4-point improvement in the mini rhinoconjunctivitis quality-of-life questionnaire (MiniRQLQ) score; that percentage was 80.3% at three months. This is the first time this QoL instrument — which measures the disease-specific, health-related QoL functional impairments considered most troublesome to patients because of their rhinoconjunctivitis — has been used to report outcomes of the technology.
• Safety: The RhinAer treatment was well-tolerated, with no headaches or significant pain-related adverse events reported. No serious device- or procedure-related adverse events occurred.

“Aerin Medical is committed to providing high-quality evidence to support appropriate use of our novel technology, with 10 significant peer-reviewed publications delivered to our otolaryngology community in the last year,” said Matt Brokaw, CEO of Aerin Medical. “Publication of these study results validates the benefits that patients are experiencing after receiving treatment with RhinAer, and we are grateful to the physicians and patients who participated in this study.”

Rhinitis, or inflammation of the mucous membrane of the nose, can include symptoms such as runny nose, congestion, itching, sneezing, coughing, and post-nasal drip. Chronic rhinitis, when symptoms last more than four consecutive weeks, can be challenging to treat. ENTs use RhinAer to directly interrupt nerve signals and help reduce chronic rhinitis symptoms.

About RhinAer

Using temperature-controlled, radiofrequency technology, RhinAer features a thin, wand-like stylus that is inserted via the nostril to deliver precise therapeutic benefits, while sparing surrounding tissues. RhinAer directly disrupts the posterior nasal nerve (PNN) that triggers excessive mucus production, treating an underlying cause of chronic rhinitis. RhinAer provides ENT physicians with a comprehensive solution for the treatment of chronic rhinitis, addressing sources of rhinorrhea (runny nose) and congestion. The procedure can be performed with a local anesthetic during an office visit, with no incisions, minimal to no downtime, and little discomfort. RhinAer received FDA 510(k) clearance in December 2019 and CE Mark in 2020. For more information, visit www.RhinAer.com.

About Aerin Medical

Aerin Medical is a privately held, venture-backed company, with U.S. offices in California and Texas. Aerin’s mission is to provide ENT physicians with non-invasive solutions for the treatment of chronic nasal conditions. The company’s products, VivAer^® for nasal airway obstruction and RhinAer^® for chronic rhinitis, leverage Aerin’s proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients’ symptoms with in-office procedures performed with local anesthetic. More than 60,000 patients have been treated with Aerin Medical products to date. For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook, Twitter, Instagram, LinkedIn and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005048/en/